We would like to frame the thesis, that a general, inhalative Xenon anesthesia (1 MAC) does not effect the sympathetic outflow and the sympathetic baroreflex reagibility under spontaneous breathing. Therefore we intend to monitor and document ECG (heartrate), pulsoximetry (SpO2), transcutanous pO2 and PCO2, invasive blood pressure (A. rad.), microneurographic results (MSA –bursts/minute or burst/100 heart beats) and baroreflexreagibility (MSA/DAP evoked by SNP or Phenylepinephrine).
Conditions
Interventions
Trade Name: Lenox
Pharmaceutical Form: Inhalation gas
INN or Proposed INN: XENON (133 XE)
CAS Number: 14932424
Current Sponsor code: 56582.00.00
Other descriptive name: Lenox
Concentration unit: % (V/
Sponsors
Air Liquide Santé International
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • age >= 18 years and =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Relevant deseases Age > 65 or < 18 Jahre Potential Pregnancyy Breastfeading females Non secure contraception Limited contractual capability Participation in other clinical trials Relationship of dependency to sponsor Contraindications concerning the IMPs: Pre-known maligna hyperthermia Increased cranial pressure Praeecalmpsia or Eclampsia Pulmonal or Airway Deseases Risk of higher oxygen supply than normal Coronary heart disease or heart failure Aorten isthmic stenosis Optikusatrophy Tabakamblyopy Leck of Vitamin B12 Metabolischer Acidosis Hypothyreosis Intrapulmonal arteriovenuous Shunts Severe hypertension Ventricular tachycardia Pheochromocytoma Intake of viagra® or other virility improving medication during the last 3 months Pre-known Hyperssensibility concerning the IMPs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluation of Muscular Sympathetic Activity under Xenon Anesthesia;Secondary Objective: Evaluation of Patients' Safety during Xenon anesthesia • Baroreflexreagibility • heart rate • arterial blood pressure • aretrial oxygen saturation and CO2 (Pulsoxymetry and transcutanousCO2-evaluation) • skin impedance • Plasmakatecholaminconcentration (Noradrenalin, Adrenalin) • Plasmaangiotensinconcentration • Plasmareninkonzentration ;Primary end point(s): Influence of Xenon anesthesia on sympathetic nerve system | — |
Countries
Germany
Outcome results
None listed